title: Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.
abstract: The underlying cause of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder, remains unknown. However, there is strong evidence that one pathophysiological mechanism, toxic protein misfolding and/or aggregation, may trigger motor neuron dysfunction and loss. Since the clinical and pathological features of sporadic and familial ALS are indistinguishable, all forms of the disease may be better understood and ultimately treated by studying pathogenesis and therapy in models expressing mutant forms of SOD1. We developed a cellular model in which cell death depended on the expression of G93A-SOD1, a mutant form of superoxide dismutase found in familial ALS patients that produces toxic protein aggregates. This cellular model was optimized for high throughput screening to identify protective compounds from a >50,000 member chemical library. Three novel chemical scaffolds were selected for further study following screen implementation, counter-screening and secondary testing, including studies with purchased analogs. All three scaffolds blocked SOD1 aggregation in high content screening assays and data on the optimization and further characterization of these compounds will be reported separately. These data suggest that optimization of these chemicals scaffolds may produce therapeutic candidates for ALS patients.
authors.affiliation: Cambria Pharmaceuticals, Cambridge, Massachusetts, USA.
authors.forename: Radhia
authors.initials: R
authors.lastname: Benmohamed
authors.forename: Anthony C
authors.initials: AC
authors.lastname: Arvanites
authors.forename: Jinho
authors.initials: J
authors.lastname: Kim
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Ferrante
authors.forename: Richard B
authors.initials: RB
authors.lastname: Silverman
authors.forename: Richard I
authors.initials: RI
authors.lastname: Morimoto
authors.forename: Donald R
authors.initials: DR
authors.lastname: Kirsch
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D000818:Animals; D016227:Benzoquinones / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D019610:Cytoprotection; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D057166:High-Throughput Screening Assays; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D018942:Macrolides / Q000494:pharmacology; D050505:Mutant Proteins / Q000378:metabolism; D016716:PC12 Cells; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D054852:Small Molecule Libraries; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism*
chemical_list: D016227:Benzoquinones; D047029:Lactams, Macrocyclic; D007976:Leupeptins; D018942:Macrolides; D050505:Mutant Proteins; D011993:Recombinant Fusion Proteins; D054852:Small Molecule Libraries; C109415:SOD1 G93A protein; D013482:Superoxide Dismutase; C035359:monorden; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde; C001277:geldanamycin